Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 9, 2013, Pages 1552-1560

  Froehlich, Janice C ^a   Hausauer, Brett J ^a   Federoff, David L ^a   Fischer, Stephen M ^a   Rasmussen, Dennis D ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alcohol; Alcohol Relapse; Alcohol Preferring (P) Rats; Alcoholism Pharmacotherapies; Noradrenergic System; Prazosin

Indexed keywords

PRAZOSIN;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; GENETIC PREDISPOSITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

RATTUS;

ALCOHOL; ALCOHOL RELAPSE; ALCOHOL-PREFERRING (P) RATS; ALCOHOLISM PHARMACOTHERAPIES; NORADRENERGIC SYSTEM; PRAZOSIN;

ALCOHOL DRINKING; ANIMALS; BREEDING; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; MALE; PRAZOSIN; RANDOM ALLOCATION; RATS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883219630     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12116     Document Type: Article

References (56)

1. Amit Z, Brown ZW, Levitan DE, Ogren SO (1977) Noradrenergic mediation of the positive reinforcing properties of ethanol. I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition. Arch Int Pharmacodyn Ther 230:65-75.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
3. Ardies CM, Morris GS, Erickson CK, Farrar RP (1989) Both acute and chronic exercise enhance in vivo ethanol clearance in rats. J Appl Physiol 66:550-560.
4. Aston-Jones G, Valentino RJ, Van Bockstaele EJ, Meyerson AT (1994) Locus coeruleus, stress, and PTSD: neurobiological and clinical parallels, in Catecholamine Function in Posttraumatic Stress Disorder: Emerging Concepts (Murburg MM ed), pp 17-62. American Psychiatric Press, Inc, Washington, DC.
5. Atkinson J, Luthi P, Sonnay M, Boillat N (1986) Effect of acute administration of prazosin on blood pressure, heart rate and plasma renin level in the conscious normotensive rat. Clin Exp Pharmacol Physiol 13:535-541.
6. Badia-Elder NE, Mosemiller AK, Elder RL, Froehlich JC (1999) Naloxone retards the expression of a genetic predisposition toward alcohol drinking. Psychopharmacology 144:205-212.
7. Bauer JH, Jones LB, Gaddy P (1984) Effects of prazosin therapy on BP, renal function, and body fluid composition. Arch Intern Med 144:1196-1200.
8. Begleiter H, Porjesz B (1999) What is inherited in the predisposition toward alcoholism? A proposed model. Alcohol Clin Exp Res 23:1125-1135.
9. Bernard A, Delattre A, Lamelin P (1964) The mechanism of action of alcohol on the gastric mucosa: its hygroscopic and dehydrating properties. Acta Gastroenterol Belg 27:129-147.
10. Brown AP, Dinger N, Levine BS (2000) Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci 39:17-21.
11. Bull LS, Pitts GC (1971) Gastric capacity and energy absorption in the force-fed rat. J Nutr 101:593-596.
12. Centers for Disease Control and Prevention: Division of Vital Statistics (2012) 2009 Mortality multiple cause vital statistics. Available at: http://www.cdc.gov/nchs/data/dvs/deaths_2009_release.pdf. Accessed September 10, 2012.
13. Collier TJ, Greene JG, Felten DL, Stevens SY, Collier KS (2004) Reduced cortical noradrenergic neurotransmission is associated with increased neophobia and impaired spatial memory in aged rats. Neurobiol Aging 25:209-221.
14. Evered MD (1983) Neuropeptides and thirst. Prog Neuropsychopharmacol Biol Psychiatry 7:469-476.
15. Farris E, Griffith J (1949) The Rat in Laboratory Investigation. 2nd ed. Hafner Publishing Company, New York.
16. Forsander OA, Sinclair JD (1992) Alcohol elimination and the regulation of alcohol consumption in AA and ANA rats. Alcohol Alcohol 27:411-416.
17. Froehlich JC (2010) Medications development: relevance and advantage of rodent models of alcohol drinking. Alcohol Clin Exp Res 34:68.
18. Froehlich JC, Federoff D, Rasmussen DD (2010) Prazosin, an α1-adrenergic receptor antagonist, maintains continued suppression of alcohol drinking during prolonged administration. Alcohol Clin Exp Res 34:19.
19. Froehlich JC, Hausauer BJ, Rasmussen DD (2013) Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. Alcohol Clin Exp Res doi: 10.1111/acer.12148 [Epub ahead of print].
20. Froehlich J, O'Malley S, Hyytiä P, Davidson D, Farren C (2003) Preclinical and clinical studies on naltrexone: what have they taught each other? Alcohol Clin Exp Res 27:533-539.
21. Garcia T, Kimeldorf DJ, Koelling RA (1955) Conditioned aversion to saccharin resulting from exposure to gamma radiation. Science 122:157-158.
22. Gillespie RJ, Lucas CC (1961) Effect of single intoxicating doses of ethanol on the gastric and intestinal mucosa of rats. Can J Biochem Physiol 39:237-241.
23. Goodman LS, Gilman A (2006) The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, Chicago.
24. Graham RM (1984) Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensives. Am J Cardiol 53:16A-20A.
25. Hieble JP, Ruffolo RRJ (1996) The use of alpha adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 33:145-160.
26. Janhunen SK, van der Zwaal EM, la Fleur SE, Adan RAH (2011) Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats. Obesity (Silver Spring) 19:1979-1986.
27. Koshy MC, Mickley D, Bourgiognie J, Blaufox MD (1977) Physiologic evaluation of a new antihypertensive agent: prazosin HCl. Circulation 55:533-537.
28. Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149-171.
29. Le AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, Shaham Y (2011) Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology 218:89-99.
30. Liles JH, Flecknell PA, Roughan J, Cruz-Madorran I (1998) Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat. Lab Anim 32:149-161.
31. Martin-Iverson MT, Pisa M, Chan E, Fibiger HC (1982) Enhanced neophobia but normal plasma corticosterone levels in rats with dorsal noradrenergic bundle lesions. Pharmacol Biochem Behav 17:639-643.
32. McAreavey D, Cumming AM, Sood VP, Leckie BJ, Morton JJ, Murray GD, Robertson JI (1981) The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man. Clin Sci (Lond) 61:457S-460S.
33. Menkes DB, Baraban JM, Aghajanian GK (1981) Prazosin selectively antagonizes neuronal responses mediated by α1-adrenoceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 317:273-275.
34. Merikangas KR, Stevens D, Fenton B, Stolar M, O'Malley SS, Woods SW, Risch N (1998) Comorbidity and familial aggregation of alcoholism and anxiety disorders. Psychol Med 28:773-788.
35. Murphy JM, Gatto GJ, Waller MB, McBride WJ, Lumeng L, Li TK (1986) Effects of scheduled access on ethanol intake by the alcohol-preferring (P) lines of rats. Alcohol 3:331-336.
36. National Institute on Alcohol and Alcohol Abuse (2008) What is a standard drink? [NIAAA Website]. Available at: http://pubs.niaaa.nih.gov/publications/practitioner/pocketguide/pocket_guide2.htm. Accessed March 11, 2013.
37. O'Malley SS, Froehlich JC (2003) Advances in the use of naltrexone: an integration of preclinical and clinical findings, in Recent Developments in Alcoholism XVI: Research on Alcoholism Treatment (Galanter M ed), pp 217-245. Kluwer Academic/Plenum Publishers, New York.
38. Oryan S, Eidi M, Eidi A, Kohanrooz B (2003) Effects of α1-adrenoceptors and muscarinic cholinoceptors on water intake in rats. Eur J Pharmacol 477:123-127.
39. Parlesak A, Billinger MHU, Schafer C, Wehner HD, Bode C, Bode JC (2004) First-pass metabolism of ethanol in human beings: effect of intravenous infusion of fructose. Alcohol 34:121-125.
40. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC (2009a) The α1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 33:264-272.
41. Rasmussen DD, Federoff D, Froehlich JC (2009b) Prazosin reduces alcohol drinking in an animal model of alcohol relapse. Alcohol Clin Exp Res 33:146.
42. Rasmussen DD, Federoff D, Froehlich JC (2009c) Prazosin reduces voluntary alcohol drinking in both non-deprived and alcohol-deprived rats selectively bred for alcohol preference. Alcohol Clin Exp Res 33:312.
43. Rasmussen DD, Wilkinson CW, Raskind MA (2006) Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during "abstinence." Alcohol 38:173-177.
44. Rogawski MA, Aghajanian GK (1982) Activation of lateral geniculate neurons by locus coeruleus or dorsal noradrenergic bundle stimulation: selective blockade by the α1-adrenoceptor antagonist prazosin. Brain Res 250:31-39.
45. Rosen A, Brodin K, Eneroth P, Brodin E (1992) Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain. Acta Physiol Scand 146:341-348.
46. Shirao I, Tsuda A, Ida Y, Tsujimaru S, Satoh H, Oguchi M, Tanaka M, Inanaga K (1988) Effect of acute ethanol administration on noradrenaline metabolism in brain regions of stressed and nonstressed rats. Pharmacol Biochem Behav 30:769-773.
47. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33:255-263.
48. Sinha R, Robinson J, O'Malley S (1998) Stress response dampening: effects of gender and family history of alcoholism and anxiety disorders. Psychopharmacology 137:311-320.
49. Southwick SM, Morgan CA III, Bremner AD, Grillon CG, Krystal JH, Nagy LM, Charney DS (1997) Noradrenergic alteration in posttraumatic stress disorder. Ann N Y Acad Sci 821:125-141.
50. Spanagel R, Montkowski A, Allingham K, Stöhr T, Shoaib M, Holsboer F, Landgraf R (1995) Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology 122:369-373.
51. Stewart RB, Gatto GJ, Lumeng L, Li TK, Murphy JM (1993) Comparison of alcohol-preferring (P) and nonpreferring (NP) rats on tests of anxiety and for the anxiolytic effects of ethanol. Alcohol 10:1-10.
52. Tombaugh TN, Pappas BA, Roberts CS, Vickers GJ, Szostak C (1983) Failure to replicate the dorsal bundle extinction effect: telencephalic norepinephrine depletion does not reliably increase resistance to extinction but does augment gustatory neophobia. Brain Res 261:231-242.
53. Verplaetse TL, Rasmussen DD, Froehlich JC, Czachowski CL (2012) Effect of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. Alcohol Clin Exp Res 36:881-886.
54. Walker BM, Rasmussen DD, Raskind MA, Koob GF (2008) The effects of α1-noradrenergic receptor antagonism on dependence-induced increases in responding for ethanol. Alcohol 42:91-97.
55. Von Wartburg JP (1980) Comparison of alcohol metabolism in humans and animals, in Animal Models in Alcohol Research (Eriksson K, Sinclair JD, Kiianmaa K eds), pp 427-443. Academic Press, New York.
56. Webb DJ, Fulton JD, Leckie BJ, Malatino LS, McAreavey D, Morton JJ, Murray GD, Robertson JI (1987) The effect of chronic prazosin therapy on the response of the renin-angiotensin system in patients with essential hypertension. J Hum Hypertens 1:195-200.